載入...
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
BACKGROUND. Borderline resectable pancreatic cancer is best treated by multimodality therapy. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) tripled the response rate and significantly increased median survival for patients with advanced pancreatic cancer and shows promise for...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AlphaMed Press
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3958454/ https://ncbi.nlm.nih.gov/pubmed/24569947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0273 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|